Vanguard Group Inc Bio Xcel Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,201,377 shares of BTAI stock, worth $408,468. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,201,377
Previous 970,430
23.8%
Holding current value
$408,468
Previous $1.24 Million
41.06%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding BTAI
# of Institutions
55Shares Held
3.14MCall Options Held
22.2KPut Options Held
40.2K-
Black Rock Inc. New York, NY441KShares$149,8320.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$101,3340.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$62,9190.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$44,1550.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny129KShares$43,7820.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $9.53M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...